Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 84,34 € (-3,49 %). La médiane est de 89,33 € (+2,22 %).
| Acheter |
11 |
| Conserver |
0 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Kiniksa significantly increases ARCALYST sales and advances IL-1 pipeline
Kiniksa reported Q2 net sales of about $243 million for ARCALYST, an increase of $29 million versus the prior quarter and the strongest growth since market launch. The company says it is profitable and is targeting a positive annual cash‑flow trajectory. KPL-387 has entered the Phase III study of the PASTEURAL program with the goal of once‑monthly dosing and a possible launch in 2028–2029; KPL-1161 is being developed as a potential quarterly option. Kiniksa sees additional market potential in recurrent pericarditis and highlights a growing prescriber base and solid payer support. » Plus sur de.investing.com
Kiniksa Pharmaceuticals reaches record high at $64.85
Kiniksa Pharmaceuticals’ stock rose to a record high of $64.85 and is up 130.88% year-to-date. The company has a market capitalization of $4.96 billion and reported revenue growth of 57% in the past year. For Q1 2026, Kiniksa reported earnings per share of $0.27 (expectation $0.21) and revenue of $214.3 million (expectation $207.1 million). InvestingPro rates the stock close to its fair value but notes an overbought RSI. » Plus sur de.investing.com
Kiniksa raises guidance after strong Q1 – ARCALYST revenue grows 56%
Kiniksa reported ARCALYST revenue of US$214.3 million in Q1 2026 (up 56% year‑on‑year) and EPS of $0.27, beating expectations. The company raised its full-year guidance for net product sales of ARCALYST to US$930–945 million (previously US$900–920 million). Net income, operating margin and cash increased substantially; management highlighted market expansion, direct‑to‑consumer marketing and ongoing clinical programs KPL‑387 and KPL‑1161. The stock rose sharply after the results and is approaching its 52‑week high. » Plus sur de.investing.com
Kiniksa reports strong Q1 2026 thanks to ARCALYST and raises full-year guidance
Kiniksa recorded significant revenue growth from ARCALYST in Q1 2026 to $214.3 million (+56% y/y) and raised its full-year guidance to $930–945 million. Net income and operating income increased markedly; earnings per share were $0.27, beating expectations. The company broadened its prescriber base and now addresses patients with a first relapse; commercial momentum and pipeline candidates KPL-387 and KPL-1161 are expected to support further growth. Liquidity and the balance sheet improved, while higher revenue-linked collaboration costs and rising R&D spending temper the margin profile. » Plus sur de.investing.com
Kiniksa Pharmaceuticals reaches profitability after strong Arcalyst growth, stock falls premarket
Kiniksa Pharmaceuticals reported Q4 2025 revenue of $202.1 million (+65% versus Q4 2024) and a net profit of $14.2 million after a net loss in the year‑ago quarter. For full-year 2025 the company posted revenue of $677.6 million (+62%) and a net income of $59 million. The strong performance was driven mainly by Arcalyst; Kiniksa has $414.1 million in cash and plans to expand the IL‑1 franchise and advance KPL‑387. Despite the results, the stock fell 6.44% premarket to $44.34. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 252,47 M | 63,82 % |
| Bénéfice brut | 134,53 M | 62,32 % |
| Bénéfice net | 41,8 M | 166,08 % |
| EBITDA | 52,57 M | 124,01 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 6,86 Md € |
Nombre d'actions | 78,57 M |
Plus haut/bas sur 52 semaines | 90,06 € - 33,57 € |
| Dividendes | Non |
Bêta | 0,08 |
Ratio P/E | 67,36 |
Ratio PEG | 0,35 |
Ratio P/B | 10,61 |
Ratio P/S | 8,00 |
Profil de l'entreprise
Kiniksa Pharmaceuticals, Ltd., une société biopharmaceutique, se consacre à la découverte, à l'acquisition, au développement et à la commercialisation de médicaments thérapeutiques destinés aux patients souffrant de maladies invalidantes présentant des besoins médicaux non satisfaits importants dans le monde entier. Ses candidats-médicaments comprennent ARCALYST, un inhibiteur de l'interleukine-1alpha et de l'interleukine-1bêta, destiné au traitement de la péricardite récurrente, une maladie cardiovasculaire inflammatoire ; le mavrilimumab, un anticorps monoclonal inhibiteur ayant achevé les essais cliniques de phase II pour le traitement de l'artérite à cellules géantes ; le vixarelimab, un anticorps monoclonal en essai clinique de phase 2a pour le traitement du prurigo nodulaire, une affection cutanée inflammatoire chronique ; et le KPL-404, un anticorps monoclonal inhibiteur de l'interaction CD40-CD154, un signal de costimulation des lymphocytes T essentiel à la maturation des lymphocytes B, au changement de classe des immunoglobulines et à la réponse immunitaire de type 1. Kiniksa Pharmaceuticals, Ltd. a été constituée en 2015 et a son siège à Hamilton, aux Bermudes.
| Nom | KINIKSA A BE-,000273235 |
| PDG | Sanj K. Patel |
| Siège social | London,
gl Bermudes |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 25/05/2018 |
| Employés | 366 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | KNSA |